Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study

doi:10.3748/wjg.v32.i8.114268

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 8

This Article

(51)

(53)

(0)

(16)

(1)

(1019)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 28, 2026; 32(8): 114268
Published online Feb 28, 2026. doi: 10.3748/wjg.v32.i8.114268

Table 3 Comparison of clinical and pathological baseline characteristics between non-progressive and progressive groups, n (%)

Variables	Total (n = 128)	Non-progressive group (n = 87)	Progressive group (n = 41)	Statistic	P value	SMD
Sex				χ² = 1.05	0.306
Male	52 (40.62)	38 (43.68)	14 (34.15)			-0.201
Female	76 (59.38)	49 (56.32)	27 (65.85)			0.201
Age				χ² = 0.00	0.975
< 60	97 (75.78)	66 (75.86)	31 (75.61)			-0.006
≥ 60	31 (24.22)	21 (24.14)	10 (24.39)			0.006
BMI, median (Q₁, Q₃)	23.94 (21.48, 26.42)	24.22 (21.83, 26.97)	22.86 (21.30, 26.31)	Z = -1.35¹	0.177	-0.343
Lesion				χ² = 4.32	0.038
< 6	96 (75.00)	70 (80.46)	26 (63.41)			-0.354
≥ 6	32 (25.00)	17 (19.54)	15 (36.59)			0.354
Max-diameter				χ² = 1.73	0.188
< 10 mm	90 (70.31)	58 (66.67)	32 (78.05)			0.275
≥ 10 mm	38 (29.69)	29 (33.33)	9 (21.95)			-0.275
SSAs				χ² = 11.15	< 0.001
No	76 (59.38)	43 (49.43)	33 (80.49)			0.784
Yes	52 (40.62)	44 (50.57)	8 (19.51)			-0.784
Bleed				χ² = 0.06	0.812
No	124 (96.88)	85 (97.70)	39 (95.12)			-0.120
Yes	4 (3.12)	2 (2.30)	2 (4.88)			0.120
Perforation				-	1.000
No	125 (97.66)	85 (97.70)	40 (97.56)			-0.009
Yes	3 (2.34)	2 (2.30)	1 (2.44)			0.009
Pathology				χ² = 0.03	0.856
G1	105 (82.03)	71 (81.61)	34 (82.93)			0.035
G2	23 (17.97)	16 (18.39)	7 (17.07)			-0.035
Horizontal margin				χ² = 0.00	0.987
Negative	117 (91.41)	79 (90.80)	38 (92.68)			0.072
Positive	11 (8.59)	8 (9.20)	3 (7.32)			-0.072
Vertical margin				-	1.000
Negative	125 (97.66)	85 (97.70)	40 (97.56)			-0.009
Positive	3 (2.34)	2 (2.30)	1 (2.44)			0.009
Lymphovascular invasion				χ² = 0.69	0.406
Negative	120 (93.75)	80 (91.95)	40 (97.56)			0.363
Positive	8 (6.25)	7 (8.05)	1 (2.44)			-0.363
Perineural invasion				-²	0.320
Negative	127 (99.22)	87 (100.00)	40 (97.56)			-0.158
Positive	1 (0.78)	0 (0.00)	1 (2.44)			0.158
Invasion depth				χ² = 2.07	0.150
M	49 (38.28)	37 (42.53)	12 (29.27)			-0.291
SM	79 (61.72)	50 (57.47)	29 (70.73)			0.291
NLR				χ² = 5.36	0.021
< 2	72 (56.25)	55 (63.22)	17 (41.46)			-0.442
≥ 2	56 (43.75)	32 (36.78)	24 (58.54)			0.442
Follow-up time, median (Q₁, Q₃)	25.50 (14.00, 58.50)	36.00 (20.00, 66.50)	14.00 (9.00, 38.00)	Z = -4.21¹	< 0.001	-0.843

¹Mann-Whitney test.

²Fisher exact.

Q₁: 1^st quartile; Q₃: 3^rd quartile; BMI: Body mass index; SSAs: Somatostatin analogs; NLR: Neutrophil-to-lymphocyte ratio.

Full Size Table

Citation: Yang ZL, Wang HK, Liu Y, Dou LZ, Zhang YM, Ng HI, He S, Chi YB, Wang GQ. Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study. World J Gastroenterol 2026; 32(8): 114268
URL: https://www.wjgnet.com/1007-9327/full/v32/i8/114268.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i8.114268

Yang ZL, Wang HK, Liu Y, Dou LZ, Zhang YM, Ng HI, He S, Chi YB, Wang GQ. Progression after endoscopic treatment for type I gastric neuroendocrine tumors: A single-center retrospective study. World J Gastroenterol 2026; 32(8): 114268 [PMID: 41809874 DOI: 10.3748/wjg.v32.i8.114268]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.